Analyst Price Target is $42.57
▲ +177.52% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $42.57, with a high forecast of $51.00 and a low forecast of $35.00. The average price target represents a 177.52% upside from the last price of $15.34.
Current Consensus is
The current consensus among 14 contributing investment analysts is to buy stock in Viridian Therapeutics. This Buy consensus rating has held steady for over two years.
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.